Researchers gave 46 older adults with insomnia either 500 mg of elemental magnesium or a placebo every day for 8 weeks. The magnesium group slept longer, fell asleep faster and scored better on an insomnia questionnaire than the placebo group. Blood tests showed higher melatonin and lower cortisol in the magnesium group, while total time in bed did not change.
Insomnia is common in later life. The authors cite estimates that 40 to 50 percent of people over 60 have it. Sleeping tablets are the usual medical answer, but the paper notes a US National Institutes of Health position that routine hypnotic drugs carry more hazard than benefit for older people. Magnesium blocks the NMDA receptor and acts on GABA, two actions linked to calming the nervous system. The team asked whether topping up magnesium would improve insomnia in older adults who were not getting enough of it.
A double-blind randomized placebo-controlled trial in Tehran, Iran, from January to March 2012. Forty-six volunteers aged 60 to 75 were enrolled, 23 women and 23 men, mean age 65 plus or minus 4.6 years. Entry required moderate or severe primary insomnia on the Insomnia Severity Index, a body mass index of 25 to 34.9, dietary magnesium below 75 percent of the recommended allowance, and serum magnesium below 0.95 mmol/L. Participants took 500 mg of elemental magnesium daily as two magnesium oxide tablets, or a matching placebo, for eight weeks. Sleep was measured by the Insomnia Severity Index and a sleep log. Fasting blood samples measured serum magnesium, renin, melatonin and cortisol. Forty-three people finished: 21 on magnesium, 22 on placebo.
Against placebo, the magnesium group showed:
Two results were not statistically significant. Total sleep time did not differ between groups, P = 0.37. Early morning awakening was marginal at P = 0.08, as was the rise in serum magnesium itself, P = 0.06.
The trial is small. Only 43 people completed it, and the sample size was calculated around serum renin, not a sleep outcome. It ran for eight weeks in one city, in people already selected for low magnesium intake and low serum magnesium. Most sleep outcomes came from self-reported logs rather than sleep laboratory recording. Physical activity rose significantly in the magnesium group, P = 0.02, which the authors attribute to better sleep but which is an uncontrolled difference. Serum magnesium barely moved, and the authors accept that serum is a poor guide to total body magnesium and that eight weeks may have been too short. The abstract reports sleep efficiency at P = 0.03 while the results table shows P = 0.006 for the same comparison. Funding came from the National Nutrition and Food Technology Research Institute of Shahid Beheshti University of Medical Sciences. The authors declared no conflict of interest.
This is a single small trial in a clinical population: adults aged 60 to 75 with diagnosed primary insomnia and documented low magnesium status. The result does not automatically extend to healthy or younger people, or to anyone whose magnesium intake is already adequate. Read it as early, largely subjective evidence of a modest signal. It does not show that magnesium lengthens total sleep, does not compare magnesium against any sleep medication, and says nothing about what happens beyond eight weeks.
That depends on the specific medication and formula. A few, like blood thinners with CurQLife or blood pressure medication with MaxiNOs, are worth a direct conversation with your doctor first. Check each formula's own FAQ section for specifics, or ask your health coach.
No, and we'd rather be upfront about it. Bacopa, the plant in BacoZest, has published human studies, though they used other bacopa extracts. OptiNOs and MaxiNOs each have human studies sponsored by their maker, Laila Nutraceuticals, which haven't been published in a journal. CurQLife's research is still early, from lab and animal studies, and we label it that way.
It depends on what you're building your routine around. BacoZest is built around bacopa, which is studied for memory.* OptiNOs supports strength and muscular endurance alongside resistance training.* MaxiNOs was studied for healthy blood vessel function.* CurQLife's research is still at the lab stage. Your health coach can help you pick a starting point.
All four are built around plant extracts. OptiNOs was reported as well tolerated in its human study, and published bacopa studies reported no serious side effects. CurQLife's safety data so far comes from lab and animal testing. Check with your doctor first if you're pregnant, nursing, on medication, or managing a health condition.
Because the patented ingredients behind our four formulas went through dedicated research, and research costs real money. A generic curcumin or bacopa supplement hasn't been tested in the form you get from us. You're paying for an ingredient with research behind it, not just a label.
Generic ingredients often haven't been studied in the specific form you're buying. Our four core formulas use patented ingredients, and we show you the research behind each one, including where it's still early.
It depends on the formula. In its study, MaxiNOs blood vessel response was higher than placebo 2 to 3 hours after the first dose.* OptiNOs and bacopa were studied over 6 and 12 weeks of daily use, so give them time. CurQLife is meant to be taken daily.
Yes. BacoZest, OptiNOs, MaxiNOs, and CurQLife are built for different goals, and none of them contain stimulants. They haven't been studied together, so ask your health coach how to fit them into your routine.
